BACE-1 inhibitors part 3: Identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells

Paul Beswick(GlaxoSmithKline (United Kingdom)), Gareth Wayne(GlaxoSmithKline (United Kingdom)), Rosalie Matico(GlaxoSmithKline (United States)), Julie A. Hawkins(Charles River Laboratories (United Kingdom)), J. Mosley(GlaxoSmithKline (United Kingdom)), Sharon Sweitzer(GlaxoSmithKline (United States)), David Riddell(Eli Lilly (United States)), Nicolas Charrier(GlaxoSmithKline (United Kingdom)), John M. Ward(University College London), Sally Redshaw(GlaxoSmithKline (United Kingdom)), Steven J. Stanway(GlaxoSmithKline (United Kingdom)), V. Soleil(GlaxoSmithKline (United Kingdom)), Ishrut Hussain(GlaxoSmithKline (United Kingdom)), David T. MacPherson(GlaxoSmithKline (United Kingdom)), Pam Theobald(GlaxoSmithKline (United Kingdom)), Alistair Stuart(GlaxoSmithKline (United Kingdom)), Kathrine J. Smith(GlaxoSmithKline (United Kingdom)), G. Maile(GlaxoSmithKline (United Kingdom)), Peter H. Milner(GlaxoSmithKline (United Kingdom)), Alan Naylor(GlaxoSmithKline (United Kingdom)), D. Vesey(GlaxoSmithKline (United Kingdom)), R. Dunsdon(GlaxoSmithKline (United Kingdom)), Alistair O’Brien(GlaxoSmithKline (United Kingdom)), Paul Rowland(GlaxoSmithKline (United Kingdom)), John Skidmore, Christopher N. Johnson, Daryl S. Walter(GlaxoSmithKline (United Kingdom)), Geoffrey Stemp(GlaxoSmithKline (United Kingdom)), Colin Dingwall(GlaxoSmithKline (United Kingdom)), Andrew Faller(GlaxoSmithKline (United Kingdom)), Robert J. Gleave(GlaxoSmithKline (United Kingdom)), Brian Clarke(GlaxoSmithKline (United Kingdom)), Emmanuel H. Demont(Age UK)
Bioorganic & Medicinal Chemistry Letters
January 4, 2008
Cited by 58


Related Papers